[Form 4] AbCellera Biologics Inc. Insider Trading Activity

Rhea-AI Filing Summary

AbCellera Biologics Inc. (ABCL) reported an insider share purchase by a company director. On 11/26/2025, the reporting person bought 50,000 common shares in an open market transaction coded as "P" at a price of $3.5692 per share. After this transaction, the director beneficially owned 221,000 common shares directly.

The filing also notes indirect ownership of an additional 5,000 common shares held by the director’s spouse. The form is filed as a Form 4 for one reporting person and indicates the director relationship to AbCellera Biologics Inc.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Montalbano John S.

(Last) (First) (Middle)

C/O ABCELLERA BIOLOGICS INC

150 W 4TH AVENUE

(Street)

VANCOUVER A1

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/26/2025		P	V	50,000	A	$3.5692	221,000	D
Common Shares								5,000	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Tryn Stimart, attorney-in-fact	11/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did AbCellera Biologics Inc. (ABCL) report?

AbCellera Biologics Inc. reported that a director purchased 50,000 common shares on 11/26/2025 in a transaction coded as "P" (open market or private purchase).

At what price were the AbCellera (ABCL) shares purchased in this Form 4?

The director purchased the 50,000 common shares at a price of $3.5692 per share.

How many AbCellera (ABCL) shares does the insider beneficially own after the transaction?

Following the reported transaction, the director beneficially owns 221,000 common shares directly and 5,000 common shares indirectly through a spouse.

What is the insider’s relationship to AbCellera Biologics Inc. (ABCL)?

The reporting person is identified as a Director of AbCellera Biologics Inc.

Is this AbCellera (ABCL) Form 4 filed for one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not a group.

Does the AbCellera (ABCL) Form 4 include any derivative securities?

The section for derivative securities is present, but no derivative transactions are listed in the provided content.